Harmony Biosciences Sinks On FDA Nod


(MENAFN- Baystreet) Unleashing AI's Next Frontier Through Enhanced Infrastructure

  • 'Madame Web' Disappoints Over Long Weekend box office
  • National Grid Flat on News of Donation
  • hsbc Slips on profit Miss
  • Amaersco Flat on Hawaiian Electric Award Previous Articles Subscribe to Get Small Cap News & Alerts Glenn Wilkin - Wednesday, February 21, 2024

    Harmony Biosciences Sinks on FDA Nod

    Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) announced that the U.S. Food and Drug Administration (FDA) granted priority review for its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric patients 6 years of age and older with narcolepsy. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action date, of June 21, 2024.

    "The FDA's decision highlights the pressing need for new treatment options for children living with narcolepsy and expedites the timeline for its decision," said Jeffrey M. Dayno, M.D., President and Chief Executive Officer at Harmony Biosciences. "We are committed to expanding the utility of pitolisant for patients with high unmet medical needs and look forward to collaborating with the FDA to potentially introduce a new, non-scheduled treatment option for children with narcolepsy."

    The FDA accepted the sNDA and granted priority review based on a Phase 3 multicenter, randomized, placebo-controlled study conducted by Bioprojet that evaluated the safety and efficacy of pitolisant in pediatric patients six to < 18 years with narcolepsy with or without cataplexy. Based on the results of this study, Bioprojet received approval from the European Medicines Agency last year extending the indication for pitolisant to include the treatment of narcolepsy in children aged six years and older, with or without cataplexy.

    HRMY lost 28 cents to $32.74.





    • About Us
    • Contact Us
    • Advertise
    • License Our Content
    • Jobs
    • Disclaimer
    • Privacy Policy

    Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks

    MENAFN21022024000212011056ID1107881026


  • Baystreet.ca

    Legal Disclaimer:
    MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.